Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 5/20 | 0.56 |
| ▸ | PRF1 | P14222 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179934 | 0.89 | SRD5A1 (0.55) | HSD17B1PRF1CA12CA1CA2 | |
| SCHEMBL4916631 | 0.81 | MAPT (0.58) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL552474 | 0.81 | ALDH1A1 (0.53) | HSD17B1CA12CA1CA2ESR1 | |
| SCHEMBL31337617 | 0.80 | BRD4 (0.55) | CA12CA1CA2ESR1CA7 | |
| SCHEMBL30583381 | 0.80 | BRD4 (0.55) | CA12CA1CA2ESR1CA7 | |
| SCHEMBL17540279 | 0.80 | HSD17B1 (0.66) | HSD17B1ESR1ESR2CYP1A2KCNH2 | |
| SCHEMBL10443684 | 0.79 | CA12 (0.57) | CA12CA1CA2ESR1CA7 | |
| SCHEMBL4424918 | 0.78 | HSD17B1 (0.68) | HSD17B1SRD5A1SRD5A2CYP1A2LMNA | |
| SCHEMBL1513411 | 0.78 | BRD4 (0.48) | MAPT | |
| SCHEMBL16351874 | 0.77 | CA1 (0.73) | CA12CA1CA2ESR1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160056383-A1 | FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND MANUFACTURING METHOD THEREOF | LG CHEM, LTD. (KR) | 2016-02-25 | — | — | US | disclosed |
| EP-2962992-A1 | FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND MANUFACTURING METHOD THEREOF | LG Chem, Ltd. (KR) | 2016-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160056383-A1 | FULLERENE DERIVATIVE, ORGANIC SOLAR CELL USING SAME, AND MANUFACTURING METHOD THEREOF | FTO, SUN2, CRY2 | HSD17B1 3023/4885PRF1 1551/4885PDK2 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.